Engineered Microbes Detect Pathogen States
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current broad spectrum antibiotics are ineffective against pathogens that develop resistance, particularly Clostridium difficile, due to their ability to form dormant spore states, leading to recurring infections and high medical costs.
Innovation Solution
Genetically engineered microbes equipped with dual pathogen state detection systems that differentiate between virulent and spore forms, allowing for targeted secretion of therapeutic agents to inhibit or kill the pathogen, minimizing impact on natural gut microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad spectrum antibiotics are used to treat pathogenic infections, then initial infection may be suppressed, but pathogen resistance develops and recurrence increases
Solution Approach 1:
The therapeutic microbe is engineered with dynamic adaptability to respond to different pathogen states. It contains multiple sensor systems that detect virulent cells, spores, and toxins, and automatically activate corresponding secretion systems to release appropriate therapeutic agents. This dynamic response mechanism allows the treatment to adapt to changing pathogen states, preventing resistance development while maintaining long-term effectiveness.
2Reliability
If broad spectrum antibiotics are used to eliminate pathogens, then infection is treated, but natural gut microbiota is suppressed
Solution Approach 1:
The therapeutic microbe employs local quality by deploying different therapeutic agents at different locations and conditions within the gut environment. The sensor-secretion system architecture ensures that specific agents are released only when and where needed - virulent-targeting agents are secreted only near virulent cells, spore-targeting agents only near spores, and toxin-neutralizing agents only when toxins are detected. This localized, conditional delivery spares natural microbiota from unnecessary exposure.
Solution Approach 2:
The therapeutic microbe acts as an intermediary between the host and pathogens. Rather than using broad-spectrum antibiotics that directly affect all bacteria, the engineered microbe intermediates the treatment process by selectively detecting pathogen states and releasing targeted therapeutic agents, thereby protecting natural microbiota while effectively treating infections.
3Ease of manufacture
If a single therapeutic agent is used to target pathogens, then manufacturing is simple, but effectiveness against different pathogen states is limited
Solution Approach 1:
The therapeutic microbe achieves multi-functionality by integrating multiple sensor systems and secretion systems into a single living platform. One engineered microbe can detect and respond to virulent cells, spores, and toxins simultaneously, making it a universal therapeutic agent that covers all major pathogen states. This approach simplifies manufacturing compared to producing multiple separate therapeutic products, as only one microbial strain needs to be developed and administered.
4Measurement precision
If multiple sensors and secretion systems are integrated into the therapeutic microbe, then pathogen state detection accuracy improves, but device complexity increases
Solution Approach 1:
The patent merges multiple detection and secretion functions into a single integrated therapeutic microbe system. Rather than using separate devices or treatments for detecting virulent cells, spores, and toxins, the engineered microbe combines all sensor-secretion pairs within one biological platform. This merging reduces overall system complexity by utilizing the natural regulatory and分泌 capabilities of the microbe, avoiding the need for multiple separate engineered systems.
Data Source
AI summary
This disclosure provides microbes engineered to detect virulent and spore states of pathogens and release an appropriate therapeutic response accordingly and compositions and methods of use of the same.